Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.59 (market cap $6.04B), while Direxion Daily S&P 500 Bull 3X Shares trades at $298.51 (market cap $7.36B). The key difference: Direxion Daily S&P 500 Bull 3X Shares is the larger of the two by market cap, and Iovance Biotherapeutics Inc. Common Stock is more actively traded (14,805,993 versus 1,835,467). Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Direxion Daily S&P 500 Bull 3X Shares for 32 Days on average.
| IOVA | SPXL | |
|---|---|---|
Market Cap | $6.04B | $7.36B |
Volume | 14,805,993 | 1,835,467 |
Sector | Health | Leveraged / Inverse |
52-Week High | $14.82 | $301.38 |
52-Week Low | $1.81 | $170.20 |
Typical Hold Time | 0 Days | 32 Days |
Enterprise Value | $5.97B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SPXL trades at $298.10, up 0.42% with a bullish technical signal from moving averages. The ETF shows neutral momentum oscillators with RSI at 66.91 suggesting mild overbought conditions. Recent news highlights S&P 500 valuation concerns despite strong earnings growth projections of 35% for 2026. The index faces concentration risks with top holdings accounting for 40% of value.
Outlook remains cautiously optimistic with seasonal patterns favoring year-end rallies, though profit growth is expected to slow to 15% in 2027. Key risks include market concentration, geopolitical uncertainty, and potential Fed policy impacts. Technical support at $289 and resistance at $300 will be critical near-term levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →
